Dr Bose on Spleen and Symptom Benefit With Pacritinib in Mye

Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.

Related Keywords

, Patient Global Impression , Myeloproliferative Neoplasms , Myelofibrosis , Mdanderson , Spleen Volume , Symptom Benefit , Asco 2023 , Pacritinib ,